Today, the process of discovering and developing a new medicine (pharma R&D) typically takes 10-15 years, costs billions of dollars, and fails more often than not. Immuneering is focused on fundamentally re-engineering this process to be faster, less expensive, and more likely to succeed. Significant improvements are now possible thanks to recent advances in AI and other computational methods, as well as a dramatic acceleration in the ability to generate high-throughput molecular-level data (e.g. genomics, transcriptomics, and binding affinity data).


At Immuneering, we have spent more than a decade making high-throughput molecular level data useful throughout the pharma R&D process. Drawing on these experiences and proprietary algorithms developed along the way, we have created a drug discovery platform that finds “hits” (the molecular structures that form the basis of new medicines) in a matter of days-weeks, rather than the months-years of target identification and high-throughput screening typically required to identify hits.


In addition to speeding up the process, Immuneering’s platform also aims to increase the success rate. Drugs typically fail clinical trials due to either toxicity or lack of efficacy. With regard to toxicity, our AI-based toxicity prediction platform provides an assessment of a drug candidate’s safety profile. With regard to efficacy, traditional pharma R&D is mostly restricted to drugs for single targets, yet such a specific intervention may be ineffective for complex diseases with feedback loops and multiple redundant pathways. Our platform readily extends from single targets to multi-targeted drugs, identifying molecules that are likely to have greater efficacy by modulating multiple aspects of disease biology in parallel.


Today, Immuneering is focused on 3 key activities:


(1) Expanding our drug discovery platform to similarly improve other aspects of pharma R&D.


(2) Discovering and developing new medicines identified using our drug discovery platform and other advanced approaches in collaboration with partners.


(3) Providing unparalleled bioinformatics services to help pharma companies make the most of their high-throughput data.


For more information contact us directly.